2015 will have results from diabetes,arthritis in the first half,Japan could be the real mover though with an expected approval for market of GVHD. Also Mesoblast can expediate a lot there other trials through Japans new regulatory fast track process.Mesoblast is on the up and up.Also there will be efficacy results later this year from the teva heart trials.Don't ask me to spell.
Timeframe for 2015, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.053(4.67%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.07 | $7.121M | 6.465M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 77525 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 70157 | 18 |
View Market Depth
| Last trade - 15.31pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |